Fanconi Anemia Complementation Group N Protein
"Fanconi Anemia Complementation Group N Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Fanconi anemia complementation group protein that contains an N-terminal DNA-binding region and seven, C-terminal, WD REPEATS. It is an essential factor in HOMOLOGOUS RECOMBINATION DNA REPAIR through its interactions with BRCA2 PROTEIN; RAD51 RECOMBINASE; and BRCA1 PROTEIN. It functions as a molecular scaffold to localize and stabilize these proteins at homologous recombination sites. Mutations in the PALB2 gene are associated with FANCONI ANEMIA complementation group N; type 3 PANCREATIC NEOPLASMS; and susceptibility to BREAST CANCER.
Descriptor ID |
D000076164
|
MeSH Number(s) |
D12.776.313.953 D12.776.624.776.051 D12.776.660.323
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Fanconi Anemia Complementation Group N Protein".
Below are MeSH descriptors whose meaning is more specific than "Fanconi Anemia Complementation Group N Protein".
This graph shows the total number of publications written about "Fanconi Anemia Complementation Group N Protein" by people in this website by year, and whether "Fanconi Anemia Complementation Group N Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2010 | 0 | 1 | 1 |
2014 | 0 | 1 | 1 |
2018 | 0 | 1 | 1 |
2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fanconi Anemia Complementation Group N Protein" by people in Profiles.
-
Seeber A, Zimmer K, Kocher F, Puccini A, Xiu J, Nabhan C, Elliott A, Goldberg RM, Grothey A, Shields AF, Battaglin F, El-Deiry WS, Philip PA, Marshall JL, Hall M, Korn WM, Lenz HJ, Wolf D, Feistritzer C, Spizzo G. Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. ESMO Open. 2020 11; 5(6):e000942.
-
Ding YC, Adamson AW, Steele L, Bailis AM, John EM, Tomlinson G, Neuhausen SL. Discovery of mutations in homologous recombination genes in African-American women with breast cancer. Fam Cancer. 2018 04; 17(2):187-195.
-
Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer. 2015 Jan; 62(1):91-8.
-
Kim JH, Choi DH, Cho DY, Ahn SH, Son BH, Haffty BG. PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations. Breast Cancer Res Treat. 2010 Jul; 122(1):303-6.